Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668

Joel M Reid, Chad A. Walden, Rui Qin, Katie L. Allen Ziegler, John L. Haslam, Roger A. Rajewski, Roger Warndahl, Cindy L. Fitting, Daniel Boring, Eva Szabo, James Crowell, Marjorie Perloff, Ling Jong, Brent A Bauer, Sumithra J Mandrekar, Matthew M. Ames, Paul John Limburg

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

SR13668, an orally active Akt pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effects of food and formulation on SR13668 bioavailability. Healthy adult volunteers were randomly assigned to receive a single, 38-mg oral dose of SR13668 in one of five different formulations, with or without food. On the basis of existing animal data, SR13668 in a PEG400/Labrasol oral solution was defined as the reference formulation. Blood samples were obtained pre- and post-agent administration for pharmacokinetic analyses. Area under the plasma concentration-time curve (AUC 0-∞) was defined as the primary endpoint. Data were analyzed and compared using established statistical methods for phase 0 trials with a limited sample size. Participants (n = 20) were rapidly accrued over a 5-month period. Complete pharmacokinetic data were available for 18 randomized participants. AUC 0-∞ values were highest in the fed state (range = 122-439 ng/mL x hours) and were statistically significantly different across formulations (P = 0.007), with Solutol HS15 providing the highest bioavailability. SR13668 time to peak plasma concentration (3 hours; range, 2-6 hours) and half-life were (11.2 ± 3.1 hours) were not formulation-dependent. Using a novel, highly efficient study design, we rapidly identified a lead formulation of SR13668 for further clinical testing. Our findings support application of the phase 0 trial paradigm to accelerate chemoprevention agent development.

Original languageEnglish (US)
Pages (from-to)347-353
Number of pages7
JournalCancer Prevention Research
Volume4
Issue number3
DOIs
StatePublished - Mar 2011

Fingerprint

Chemoprevention
Clinical Trials
Biological Availability
Area Under Curve
Pharmacokinetics
Food
Sample Size
Half-Life
SR 13668
Healthy Volunteers
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. / Reid, Joel M; Walden, Chad A.; Qin, Rui; Allen Ziegler, Katie L.; Haslam, John L.; Rajewski, Roger A.; Warndahl, Roger; Fitting, Cindy L.; Boring, Daniel; Szabo, Eva; Crowell, James; Perloff, Marjorie; Jong, Ling; Bauer, Brent A; Mandrekar, Sumithra J; Ames, Matthew M.; Limburg, Paul John.

In: Cancer Prevention Research, Vol. 4, No. 3, 03.2011, p. 347-353.

Research output: Contribution to journalArticle

Reid, JM, Walden, CA, Qin, R, Allen Ziegler, KL, Haslam, JL, Rajewski, RA, Warndahl, R, Fitting, CL, Boring, D, Szabo, E, Crowell, J, Perloff, M, Jong, L, Bauer, BA, Mandrekar, SJ, Ames, MM & Limburg, PJ 2011, 'Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668', Cancer Prevention Research, vol. 4, no. 3, pp. 347-353. https://doi.org/10.1158/1940-6207.CAPR-10-0313
Reid, Joel M ; Walden, Chad A. ; Qin, Rui ; Allen Ziegler, Katie L. ; Haslam, John L. ; Rajewski, Roger A. ; Warndahl, Roger ; Fitting, Cindy L. ; Boring, Daniel ; Szabo, Eva ; Crowell, James ; Perloff, Marjorie ; Jong, Ling ; Bauer, Brent A ; Mandrekar, Sumithra J ; Ames, Matthew M. ; Limburg, Paul John. / Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. In: Cancer Prevention Research. 2011 ; Vol. 4, No. 3. pp. 347-353.
@article{5030596323734960a717944affa6b9c4,
title = "Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668",
abstract = "SR13668, an orally active Akt pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effects of food and formulation on SR13668 bioavailability. Healthy adult volunteers were randomly assigned to receive a single, 38-mg oral dose of SR13668 in one of five different formulations, with or without food. On the basis of existing animal data, SR13668 in a PEG400/Labrasol oral solution was defined as the reference formulation. Blood samples were obtained pre- and post-agent administration for pharmacokinetic analyses. Area under the plasma concentration-time curve (AUC 0-∞) was defined as the primary endpoint. Data were analyzed and compared using established statistical methods for phase 0 trials with a limited sample size. Participants (n = 20) were rapidly accrued over a 5-month period. Complete pharmacokinetic data were available for 18 randomized participants. AUC 0-∞ values were highest in the fed state (range = 122-439 ng/mL x hours) and were statistically significantly different across formulations (P = 0.007), with Solutol HS15 providing the highest bioavailability. SR13668 time to peak plasma concentration (3 hours; range, 2-6 hours) and half-life were (11.2 ± 3.1 hours) were not formulation-dependent. Using a novel, highly efficient study design, we rapidly identified a lead formulation of SR13668 for further clinical testing. Our findings support application of the phase 0 trial paradigm to accelerate chemoprevention agent development.",
author = "Reid, {Joel M} and Walden, {Chad A.} and Rui Qin and {Allen Ziegler}, {Katie L.} and Haslam, {John L.} and Rajewski, {Roger A.} and Roger Warndahl and Fitting, {Cindy L.} and Daniel Boring and Eva Szabo and James Crowell and Marjorie Perloff and Ling Jong and Bauer, {Brent A} and Mandrekar, {Sumithra J} and Ames, {Matthew M.} and Limburg, {Paul John}",
year = "2011",
month = "3",
doi = "10.1158/1940-6207.CAPR-10-0313",
language = "English (US)",
volume = "4",
pages = "347--353",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668

AU - Reid, Joel M

AU - Walden, Chad A.

AU - Qin, Rui

AU - Allen Ziegler, Katie L.

AU - Haslam, John L.

AU - Rajewski, Roger A.

AU - Warndahl, Roger

AU - Fitting, Cindy L.

AU - Boring, Daniel

AU - Szabo, Eva

AU - Crowell, James

AU - Perloff, Marjorie

AU - Jong, Ling

AU - Bauer, Brent A

AU - Mandrekar, Sumithra J

AU - Ames, Matthew M.

AU - Limburg, Paul John

PY - 2011/3

Y1 - 2011/3

N2 - SR13668, an orally active Akt pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effects of food and formulation on SR13668 bioavailability. Healthy adult volunteers were randomly assigned to receive a single, 38-mg oral dose of SR13668 in one of five different formulations, with or without food. On the basis of existing animal data, SR13668 in a PEG400/Labrasol oral solution was defined as the reference formulation. Blood samples were obtained pre- and post-agent administration for pharmacokinetic analyses. Area under the plasma concentration-time curve (AUC 0-∞) was defined as the primary endpoint. Data were analyzed and compared using established statistical methods for phase 0 trials with a limited sample size. Participants (n = 20) were rapidly accrued over a 5-month period. Complete pharmacokinetic data were available for 18 randomized participants. AUC 0-∞ values were highest in the fed state (range = 122-439 ng/mL x hours) and were statistically significantly different across formulations (P = 0.007), with Solutol HS15 providing the highest bioavailability. SR13668 time to peak plasma concentration (3 hours; range, 2-6 hours) and half-life were (11.2 ± 3.1 hours) were not formulation-dependent. Using a novel, highly efficient study design, we rapidly identified a lead formulation of SR13668 for further clinical testing. Our findings support application of the phase 0 trial paradigm to accelerate chemoprevention agent development.

AB - SR13668, an orally active Akt pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effects of food and formulation on SR13668 bioavailability. Healthy adult volunteers were randomly assigned to receive a single, 38-mg oral dose of SR13668 in one of five different formulations, with or without food. On the basis of existing animal data, SR13668 in a PEG400/Labrasol oral solution was defined as the reference formulation. Blood samples were obtained pre- and post-agent administration for pharmacokinetic analyses. Area under the plasma concentration-time curve (AUC 0-∞) was defined as the primary endpoint. Data were analyzed and compared using established statistical methods for phase 0 trials with a limited sample size. Participants (n = 20) were rapidly accrued over a 5-month period. Complete pharmacokinetic data were available for 18 randomized participants. AUC 0-∞ values were highest in the fed state (range = 122-439 ng/mL x hours) and were statistically significantly different across formulations (P = 0.007), with Solutol HS15 providing the highest bioavailability. SR13668 time to peak plasma concentration (3 hours; range, 2-6 hours) and half-life were (11.2 ± 3.1 hours) were not formulation-dependent. Using a novel, highly efficient study design, we rapidly identified a lead formulation of SR13668 for further clinical testing. Our findings support application of the phase 0 trial paradigm to accelerate chemoprevention agent development.

UR - http://www.scopus.com/inward/record.url?scp=79955876707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955876707&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-10-0313

DO - 10.1158/1940-6207.CAPR-10-0313

M3 - Article

C2 - 21372034

AN - SCOPUS:79955876707

VL - 4

SP - 347

EP - 353

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 3

ER -